Geneva Advisors LLC Takes Position in NeoGenomics, Inc. (NEO)
Geneva Advisors LLC purchased a new position in NeoGenomics, Inc. (NASDAQ:NEO) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 123,771 shares of the medical research company’s stock, valued at approximately $1,109,000. Geneva Advisors LLC owned about 0.16% of NeoGenomics as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. Cadence Capital Management LLC raised its stake in shares of NeoGenomics by 5.8% in the second quarter. Cadence Capital Management LLC now owns 150,419 shares of the medical research company’s stock worth $1,348,000 after buying an additional 8,241 shares in the last quarter. William Blair Investment Management LLC raised its stake in shares of NeoGenomics by 10.4% in the second quarter. William Blair Investment Management LLC now owns 788,299 shares of the medical research company’s stock worth $7,063,000 after buying an additional 74,502 shares in the last quarter. Blair William & Co. IL raised its stake in shares of NeoGenomics by 8.1% in the second quarter. Blair William & Co. IL now owns 377,672 shares of the medical research company’s stock worth $3,384,000 after buying an additional 28,213 shares in the last quarter. Gamco Investors INC. ET AL raised its stake in shares of NeoGenomics by 29.5% in the second quarter. Gamco Investors INC. ET AL now owns 99,700 shares of the medical research company’s stock worth $893,000 after buying an additional 22,700 shares in the last quarter. Finally, Teton Advisors Inc. raised its stake in shares of NeoGenomics by 8.8% in the second quarter. Teton Advisors Inc. now owns 197,407 shares of the medical research company’s stock worth $1,769,000 after buying an additional 16,000 shares in the last quarter. 80.81% of the stock is currently owned by hedge funds and other institutional investors.
NeoGenomics, Inc. (NASDAQ NEO) opened at 9.24 on Monday. The stock’s market cap is $733.55 million. The company’s 50-day moving average price is $9.26 and its 200-day moving average price is $8.30. NeoGenomics, Inc. has a 12 month low of $6.90 and a 12 month high of $9.93.
NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings data on Tuesday, July 25th. The medical research company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.03. NeoGenomics had a negative net margin of 2.81% and a positive return on equity of 6.09%. The firm had revenue of $66.09 million for the quarter, compared to analysts’ expectations of $62.95 million. During the same period in the previous year, the company posted $0.04 EPS. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. Equities analysts forecast that NeoGenomics, Inc. will post $0.18 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Geneva Advisors LLC Takes Position in NeoGenomics, Inc. (NEO)” was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://theolympiareport.com/2017/08/28/geneva-advisors-llc-takes-position-in-neogenomics-inc-neo.html.
A number of brokerages have recently issued reports on NEO. Gabelli began coverage on NeoGenomics in a research note on Thursday. They issued a “buy” rating and a $9.00 price target on the stock. ValuEngine upgraded NeoGenomics from a “sell” rating to a “hold” rating in a research report on Monday, August 7th. Zacks Investment Research upgraded NeoGenomics from a “sell” rating to a “hold” rating in a research report on Saturday, July 29th. BidaskClub downgraded NeoGenomics from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Finally, BTIG Research reiterated a “buy” rating and set a $11.00 price objective on shares of NeoGenomics in a research report on Sunday, May 28th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $10.17.
In related news, Director Alison L. Hannah purchased 20,000 shares of the stock in a transaction dated Thursday, July 27th. The shares were acquired at an average cost of $9.19 per share, for a total transaction of $183,800.00. Following the acquisition, the director now directly owns 38,782 shares in the company, valued at approximately $356,406.58. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Steven A. Ross sold 70,833 shares of the business’s stock in a transaction on Monday, June 5th. The shares were sold at an average price of $7.76, for a total transaction of $549,664.08. Following the transaction, the insider now owns 4,500 shares in the company, valued at $34,920. The disclosure for this sale can be found here. Insiders own 12.20% of the company’s stock.
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.